株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

乳癌治療市場

Breast Cancer Therapies Markets

発行 TriMark Publications 商品コード 243424
出版日 ページ情報 英文 271 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: TriMark Publications社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
乳癌治療市場 Breast Cancer Therapies Markets
出版日: 2012年11月01日 ページ情報: 英文 271 Pages
概要

乳癌治療は新たな時代に入りつつあります。新規参入者は薬剤プロファイルと充実した臨床開発プログラムを持つことで、厳しい法規制環境やコスト削減などといった参入における障壁を克服する必要があります。

当レポートでは、乳癌の薬剤治療環境を包括的に分析し、乳癌治療の主なモダリティおよび薬剤の動向、ジェネリック化、特許失効、薬剤の不足、償還、個別化医療などの市場への影響、パイプラインの動向、法規制環境などをまとめ、概略下記の構成で取り上げております。

第1章 概要

第2章 乳癌について

  • 腫瘍形成
  • 乳癌の分類
  • 乳癌のリスクファクター
  • 乳癌の治療オプション
    • 乳癌の予防
    • 化学的予防
    • 予防的手術
    • 放射線治療
    • 全身療法
    • 標的療法
    • 化学療法
    • ホルモン療法

第3章 乳癌の世界・地域データ

  • 世界の乳癌統計
  • 米国
  • カナダ
  • OECD諸国のスクリーニング・生存率・死亡率
  • 英国
  • オーストラリア
  • 中国
  • インド
  • 主要7ヵ国市場における乳癌:概要

第4章 乳癌治療に用いられる薬剤

  • 化学療法の主要クラス
  • ホルモン治療
  • 標的薬剤治療

第5章 HER2陽性乳癌のゲームチェンジャー

  • 最盛期における標的HER2治療
  • HER2陽性癌について
  • 分子標的薬剤
  • HER2陽性乳癌の予測試験
  • 新しいHER2標的オプション
  • RochesのHER2ポートフォリオと癌パイプライン
  • ハーセプチン単独治療失敗後のタイケルブの有効性のデータ予測
  • HER2標的薬剤の選定を支援する新しい診断
  • HER2標的治療の遠い将来

第6章 ER陽性乳癌のゲームチェンジャー

  • ER陽性乳癌について
  • ER陽性乳癌の補助的化学療法
  • ER陽性乳癌の補助的ホルモン治療
  • アフィニトール:ER陽性乳癌のゲームチェンジャーとなる見込み
  • Novartisの癌パイプライン
  • 骨転移の低減を示すビスホスホネート

第7章 TNBC(Triple Negative Breast Cancer)

  • アバスチン
  • 開発中の血管新生阻害剤
  • PARP阻害剤

第8章 化学療法における進歩

  • 化学療法の治療基準
  • 新しい化学療法
  • 新しい方法での既存の化学療法の利用
  • 化学療法の組成変更
  • 化学療法と医薬品不足の危機
  • 将来の動向:テーラーメイドの治療
  • 高齢患者
  • 補助的化学療法:ER陽性乳癌
  • 補助的化学療法:HER2陽性乳癌

第9章 乳癌治療におけるバイオマーカー・分子診断・個別化医療

  • 乳癌治療のゲームチェンジャーとしてのマーカー・診断:概要
  • 個別化医療:応用バイオマーカー・コンパニオン診断
  • 多重遺伝子診断検査
  • バイオマーカー:薬剤耐性と毒性
  • 乳癌における個別化医療とコンパニオン診断検査
  • HER2とハーセプチン
  • BayerのAdviaケンタウルスHER2アッセイ
  • 上皮成長因子受容体コンパニオン
  • HER2アッセイの販売企業
  • 創薬におけるエンドポイントとしてのバイオマーカー
  • コンパニオン診断のリスクと不確定性
  • バイオマーカー・コンパニオン診断・規制環境

第10章 乳癌治療のための薬剤開発

  • PI3k/mTOR経路の標的薬剤
  • HER2標的薬剤
  • VEGFモジュレーター
  • 生物学的製剤
  • ワクチン
  • パイプライン薬剤の安全性プロファイルの概要

第11章 法規制動向:当局による影響

  • 規制動向:イントロダクション
  • Avastinのケーススタディ:全体の生存者データに注目する当局
  • ケーススタディ:T-DMIとアンメットニーズ
  • ケーススタディ:Halavenと治験デザイン
  • 医薬品市販後監視
  • 長期的成果に注目する当局
  • 複合治療に対する法規制動向
  • 緊縮処置
  • 償還
  • 米国の医療改革と法規制への潜在的影響
  • 新しいPDUFA V Recommendations
  • ジェネリック薬と薬剤の不足
  • バイオマーカー・コンパニオン診断・法規制上のパスウェイ
  • 2012年のバイオシミラーの規制ガイダンス
  • オフラベル利用とパブリケーションのベストプラクティス
  • 将来の法規制環境

第12章 乳癌治療:市場分析

  • 乳癌治療薬市場の成長と新規参入企業
  • 米国の乳癌市場

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TMRBCT12-1101

Abstract

Breast cancer therapies are entering a new era as game-changers emerge for each of the major breast cancer patient populations. New market entrants must possess drug profiles and a savvy clinical development program to overcome such barriers to entry as a stringent regulatory environment and the incursion of cost containment within oncology. This TriMark Publications report provides comprehensive information on major and minor shapers of the breast cancer drug treatment landscape. The study includes detailed discussions on the impact of critical factors, such as genericization, patent cliffs, drug shortages, reimbursement, predictive testing and personalized medicine, to help current and contemplative drug sponsors navigate the breast cancer pharmacotherapeutic market. Moreover, this report contains a detailed analysis of each of the seven main modalities of breast cancer therapies, i.e., hormone therapy, surgery, radiation, molecular targeted therapy, chemotherapy, hormone treatment and targeted drug therapy. Additionally, this study examines prescribing trends and the arrival of the first biosimilar agents and electronic records in post-marketing surveillance.

Table of Contents

1. Overview

  • 1.1. About This Report
  • 1.2. Scope of This Report
  • 1.3. Objectives
  • 1.4. Methodology
  • 1.5. Drugs Covered in This Report
  • 1.6. Summary of Major Findings

2. About Breast Cancer

  • 2.1. Tumorigenesis
  • 2.2. Classification of Breast Cancer
  • 2.3. Risk Factors of Breast Cancer
    • 2.3.1. Gender, Age and Reproductive Status
    • 2.3.2. Genetic Mutation and Family History
    • 2.3.3. Environmental Factors
    • 2.3.4. Breast Density
  • 2.4. The Various Options for Treating Breast Cancer
    • 2.4.1. Prevention of Breast Cancer
    • 2.4.2. Chemoprevention
    • 2.4.3. Prophylactic Surgery
    • 2.4.4. Radiation Therapy
    • 2.4.5. Systemic Therapy
    • 2.4.6. Targeted Therapy
    • 2.4.7. Chemotherapy
    • 2.4.8. Hormone Therapy

3. Global and Regional Data on Breast Cancer

  • 3.1. Global Breast Cancer Statistics, 2012
  • 3.2. Breast Cancer in the U.S.
    • 3.2.1. U.S. Breast Cancer Statistics at a Glance
    • 3.2.2. Breast Cancer Occurrence in the U.S.
    • 3.2.3. Geographic Differences in Breast Cancer Rates in the U.S.
    • 3.2.4. Breast Cancer Mortality Rate in the U.S.
    • 3.2.5. Breast Cancer in the U.S. by Age
    • 3.2.6. Changing Trends in In Situ Breast Cancer
    • 3.2.7. Changing Trends in Invasive Breast Cancer in the U.S.
    • 3.2.8. Breast Cancer in the U.S. by Tumor Size
    • 3.2.9. Breast Cancer by Age and Ethnicity in the U.S.
    • 3.2.10. U.S.: Early Detection of Breast Cancer
      • 3.2.10.1. Breast Cancer Screening in the U.S.
  • 3.3. Breast Cancer in Canada
  • 3.4. Breast Cancer Screening, Survival and Mortality in OECD Countries
  • 3.5. Breast Cancer in U.K.
    • 3.5.1. Female Breast Cancer by Age in U.K.
  • 3.6. Breast Cancer in Australia
  • 3.7. Breast Cancer in China
    • 3.7.1. Treatment Patterns in China for Breast Cancer
  • 3.8. Burden of Breast Cancer in India
  • 3.9. Overview of Breast Cancer Incidence in Seven Major Markets

4. Pharmaceutical Drugs Used in Breast Cancer Treatment

  • 4.1. Selected Classes of Chemotherapies
    • 4.1.1. Chemotherapies Available as Generics
    • 4.1.2. Branded Chemotherapies
  • 4.2. Hormone Treatments
  • 4.3. Targeted Drug Therapy

5. Game Changers for Her2+ Breast Cancer for the Current Decade

  • 5.1. Targeted Her2 Therapies in their Prime
  • 5.2. About Her2+ Carcinoma
  • 5.3. Molecular Targeted Agents
    • 5.3.1. Herceptin
      • 5.3.1.1. Mechanism of Action of Herceptin
      • 5.3.1.2. Drug Profile of Herceptin
      • 5.3.1.3. Herceptin Resistance
      • 5.3.1.4. Herceptin Product Positioning
      • 5.3.1.5. Herceptin in the Adjuvant Setting
      • 5.3.1.6. Herceptin Biosimilars in Development
      • 5.3.1.7. Herceptin SC Reformulation
  • 5.4. Predictive Testing for Her2+ Breast Cancer
  • 5.5. New and Emerging Her2 Targeted Options
    • 5.5.1. Pertuzumab
    • 5.5.2. T-DM: Chemotherapy with Fewer Side Effects to Win the Patients
  • 5.6. Roches Her2 Portfolio and Oncology Pipeline
  • 5.7. Data Prediction of Tykerb Utility after Failure of Herceptin Monotherapy
    • 5.7.1. ALTTO and NEO-ALTTO: Drive Her2+ Tumors into Adjuvant Setting
    • 5.7.2. TEACH Trial
    • 5.7.3. Tykerb Product Positioning
    • 5.7.4. GSKs Oncology Pipeline
  • 5.8. Emerging Diagnostics to Aid Her2 Targeted Drug Selection
  • 5.9. The More Distant Future of Her2 Targeted Therapy
    • 5.9.1. Afinitor
    • 5.9.2. Afatinib
    • 5.9.3. Neratinib

6. Game Changers for Estrogen Receptor Positive Breast Cancer for Current Decade

  • 6.1. About ER+ Breast Cancer
    • 6.1.1. Standard of Care for the Treatment of ER+ Breast Cancer
  • 6.2. Adjuvant Chemotherapy in ER+ Breast Cancer
  • 6.3. Adjuvant Hormone Therapy in ER+ Breast Cancer
  • 6.4. Afinitor Expected to be a Game Changer in ER+ Breast Cancer
    • 6.4.1. mTOR/PI3k Resistance
  • 6.5. Novartis Oncology Pipeline
  • 6.6. Biphosphonates Shown to Reduce Bone Metastases

7. Triple Negative Breast Cancer (TNBC)

  • 7.1. Avastin
  • 7.2. Angiogenesis Drugs in Development
  • 7.3. PARP Inhibitors

8. Advances in Chemotherapy

  • 8.1. Standard of Care for Chemotherapy
    • 8.1.1. Physician Preference
  • 8.2. New and Emerging Chemotherapies
  • 8.3. Using Existing Chemotherapies in Novel Ways
  • 8.4. Chemotherapies Reformulations
  • 8.5. Chemotherapies and Drug Shortage Crisis
  • 8.6. Future Trends: Tailoring Care
  • 8.7. Elderly Patients
  • 8.8. Adjuvant Chemotherapy in ER+ Breast Cancer
  • 8.9. Adjuvant Chemotherapy in Her2+ Breast Cancer

9. Biomarkers, Molecular Diagnostics and Personalized Medicine in Breast Cancer Treatment

  • 9.1. Overview of Markers and Diagnostics as Game Changers in Breast Cancer Treatment
  • 9.2. Personalized Medicine: Applied Biomarkers and Companion Diagnostics
  • 9.3. Multigene Diagnostic Tests
  • 9.4. Biomarkers: Drug Tolerability and Toxicity
  • 9.5. Personalized Medicine and Companion Diagnostic Tests in Breast Cancer
  • 9.6. Her2 and Herceptin
  • 9.7. Bayers Advia Centaur Her2 Assay
  • 9.8. Epidermal Growth Factor Receptor Companions
  • 9.9. Companies Marketing Her2 Assays
    • 9.9.1. Myriads BRCA Companion Diagnostics Testing for BioMarins PARP Inhibitor BMN 673
  • 9.10. Biomarkers as Endpoints in Drug Discovery
  • 9.11. Risks and Uncertainties of Companion Diagnostics
  • 9.12. Biomarkers, Companion Diagnostics and Regulatory Environment

10. Drug Development for the Treatment of Breast Cancer

  • 10.1. Targeted Drugs of the PI3k/mTOR Pathway
  • 10.2. Her2 Targeted Agents
    • 10.2.1. Neratinib
    • 10.2.2. Afatinib
  • 10.3. VEGF Modulators
  • 10.4. Biologics
  • 10.5. Vaccines
  • 10.6. Overview of Safety Profiles of Pipeline Agents

11. Regulatory Trends: How Authorities May Change the Game

  • 11.1. Introduction to Regulatory Trends
  • 11.2. Case Study Avastin: Regulators Look to Overall Survivor Data
  • 11.3. Case Study: T-DMI and Unmet Need
  • 11.4. Case Study: Halaven and Trial Design
  • 11.5. Postmarketing Surveillance
  • 11.6. Regulators Look Towards Longer Term Outcomes
  • 11.7. Regulatory Trends for Combination Therapies
  • 11.8. Austerity Measures
  • 11.9. Reimbursement
  • 11.10. U.S. Healthcare Reform and its Potential Impact on Regulation
  • 11.11. New PDUFA V Recommendations
  • 11.12. Generics and Drug Shortages
  • 11.13. Biomarker, Companion Diagnostics and the Regulatory Pathway
    • 11.13.1. Regulatory Perspectives on Pharmacogenomics and Biomarker Validation
    • 11.13.2. Role of Governmental Agencies in Driving the Adoption of Companion Diagnostics
    • 11.13.3. Role of Insurance Industry in Driving Adoption of Pharmacogenomics
    • 11.13.4. Role of Pharma Industry in Driving Adoption of Pharmacogenomics
    • 11.13.5. FDA Guidance Document on Co-Development
    • 11.13.6. Role of Diagnostic Industry in Driving the Adoption of Pharmacogenomics
  • 11.14. 2012 Regulatory Guidance for Biosimilars
  • 11.15. Off-Label Use and Good Publication Practices
  • 11.16. The Future Regulatory Environment for Oncology

12. Breast Cancer Therapies: Market Analysis

  • 12.1. Growth in Breast Cancer Drug Market and the New Entrants
    • 12.1.1. Market for Her2+ Drugs
    • 12.1.2. Global Market for Breast Cancer Hormonal Therapies
    • 12.1.3. Declining Revenue for Aromatase Inhibitors
    • 12.1.4. Market for Targeted Therapy in Breast Cancer
    • 12.1.5. Shortage of Chemotherapy Drugs
  • 12.2. Breast Cancer Market in the U.S.
    • 12.2.1. Growth in Inpatient Breast Cancer Services in the U.S.
    • 12.2.2. Outpatient Breast Cancer Services in the U.S.
    • 12.2.3. Chemotherapy Market in the U.S.
    • 12.2.4. Number of Chemotherapy Patients with Breast Cancer in the U.S.
    • 12.2.5. Number of Breast Cancer Surgeries in the U.S.
    • 12.2.6. U.S. Market for Conventional Breast Cancer Treatments
    • 12.2.7. U.S. Market for Standard Imaging Procedures in Breast Cancer
    • 12.2.8. U.S. Market for Advanced Breast Imaging Procedures

APPENDIXES:

  • Appendix 1: Breast Cancer Drug Therapies: Marketed and Development
  • Appendix 2: A Womans Guide to Breast Cancer
  • Appendix 2.1: Breast Biopsy
  • Appendix 2.2: Staging of Breast Cancer
  • Appendix 2.3: Treatment Options
  • Appendix 3: Cancer Treatment and Survivorship
  • Appendix 3.1: Female Breast Cancer
  • Appendix 3.1.1: Treatment and Survival After Breast Cancer
  • Appendix 3.1.2: Special Concerns of Breast Cancer Survivors
  • Appendix 3.2: Childhood Cancer
  • Appendix 3.2.1: Treatment and Survival for Childhood Cancer
  • Appendix 3.3: Colon and Rectum Cancer
  • Appendix 3.3.1: Treatment and Survival for Colon and Rectum Cancer Patients
  • Appendix 3.4: Leukemia and Lymphomas
  • Appendix 3.4.1: Treatment and Survival for Leukemia and Lymphoma Patients
  • Appendix 3.5: Lung and Bronchus Cancer
  • Appendix 3.5.1: Treatment and Survival for Lung and Bronchus Cancer Patients
  • Appendix 3.6: Melanoma
  • Appendix 3.6.1: Treatment and Survival for Melanoma Patients
  • Appendix 3.7: Prostate Cancer
  • Appendix 3.7.1: Treatment and Survival Rate for Prostate Cancer Patients
  • Appendix 3.8: Testicular Cancer
  • Appendix 3.8.1: Treatment and Survival for Testicular Cancer Patients
  • Appendix 3.9: Thyroid Cancer
  • Appendix 3.9.1: Treatment and Survival Rate for Thyroid Cancer Patients
  • Appendix 3.10: Urinary Bladder Cancer
  • Appendix 3.10.1: Treatment and Survival Rate for Urinary Bladder Cancer Patients
  • Appendix 3.11: Uterine Corpus
  • Appendix 3.11.1: Treatment and Survival of Uterine Corpus Patients
  • Appendix 4: U.S. Spending on Cancer
  • Appendix 5: Oncology Drugs and Companion Diagnostics
  • Appendix 6: References

INDEX OF FIGURES

  • Figure 3.1: Breast Cancer Burden by Geography, 2009
  • Figure 3.2: Breast Cancer Incidence Worldwide
  • Figure 3.3: Lifetime Risk of Breast Cancer Worldwide
  • Figure 3.4: Breast Cancer Death Rate in the U.S. by Race and Ethnicity, 1975-2007
  • Figure 3.5: Age-Specific Female Breast Cancer Incidence and Mortality Rates in the U.S.
  • Figure 3.6: Incidence Rates of In Situ Breast Cancer by Age in the U.S., 1975-2008
  • Figure 3.7: Incidence Rates of Invasive Breast Cancer by Age, 1975-2008
  • Figure 3.8: Breast Cancer Incidence Rates by Tumor Size (? 2.0 cm) and Race, 1989-2008
  • Figure 3.9: Breast Cancer Rate (Tumor Size = 2.1-5.0 cm) in the U.S., 1989-2008
  • Figure 3.10: Localized Breast Cancer Rates in the U.S. by Race, 1976-2008
  • Figure 3.11: Female Breast Cancer Incidence and Mortality Rates by Race and Ethnicity in the U.S.
  • Figure 3.12: Percent of All Estimated Cancer Cases in Canadian Women, 2012
  • Figure 3.13: Breast Cancer Screening in women Aged 50-69 in OECD Countries, 2000 and 2009
  • Figure 3.14: Breast Cancer Five-Year Relative Survival Rate in OECD Countries, 1997-2009
  • Figure 3.15: Female Breast Cancer Mortality in OECD Countries, 2000 and 2009
  • Figure 3.16: Number of New Cases per Year and AS Rate in U.K., 2009
  • Figure 3.17: Estimated Breast Cancer Incidence in Australia, 2006-2015
  • Figure 3.18: Age-Standardized Incidence and Mortality Rates of the Most Common Cancers in India
  • Figure 5.1: Schematic Representation of Mechanism of Action of Herceptin
  • Figure 5.2: Blocking of Her2 Dimerization by Herceptin
  • Figure 5.3: Design of Herceptin H0648g Pivotal Trial
  • Figure 5.4: Increased Response Rate by the Addition of Xeloda to Herceptin Therapy
  • Figure 5.5: Extended Survival by 4.8 Months in Herceptin plus Xeloda Therapy
  • Figure 5.6: Herceptins-Black Box Warning
  • Figure 5.7: Clinical Benefit of Herceptin Shown in Four Pivotal Trials
  • Figure 5.8: Example of Her2 ICH and FISH
  • Figure 5.9: Her2 Expression via the Inform Dual ISH Assay
  • Figure 5.10: Interception of EGF Pathway at Different Points by Herceptin, Tykerb and Pertuzumab
  • Figure 5.11: CLEOPATRA Trial Design
  • Figure 5.12: CLEOPATRA Study Progression Free Survival
  • Figure 5.13: CLEOPATRA Safety Study
  • Figure 5.14: T-DM1 Study Design
  • Figure 5.15: T-DM1 Results, Phase II Evaluations
  • Figure 5.16: Complimentary Mechanisms of Action of Roches-Her2 Agents
  • Figure 5.17: Roches HER Targeted Therapy Clinical Development Program
  • Figure 5.18: Roches Oncology Pipeline, Phase II and Later
  • Figure 5.19: Tykerb/Tyverb: The Oral Her2 Blocking Agent
  • Figure 5.20: Tykerb/Tryverb Works Differently than Herceptin, but on the Same Target
  • Figure 5.21: EGF100151 Study Design
  • Figure 5.22: Efficacy of Tykerb in the EGF100151 Study
  • Figure 5.23: Tykerb Safety and Tolerability: The EGF100151 Study
  • Figure 5.24: ALTTO Study Designs
  • Figure 5.25: NEO-ALTTO Study Design
  • Figure 5.26: Strong Efficacy for the Combination of Herceptin and Tykerb in NEO-ALTTO
  • Figure 5.27: Benefit in Hormone Receptor Negative and -Positive Her2 Tumors
  • Figure 5.28: GSKs-Oncology Pipeline Includes Expanded and New Indications for Tykerb
  • Figure 6.1: Response Rates to Endocrine Manipulation in ER+ Patients, Based on Receptor Type
  • Figure 6.2: Adjuvant Chemotherapy in ER+ Breast Cancer
  • Figure 6.3: Novartis-BOLERO Registrational Program for Afinitor in Breast Cancer
  • Figure 6.4: BOLERO-2 Study Design
  • Figure 6.5: BOLERO-2 Progression Free Survival, Local
  • Figure 6.6: BOLERO-2 Progression Free Survival, Central
  • Figure 6.7: BOLERO-2 Progression Free Survival, Subgroups
  • Figure 6.8: BOLERO-2 Overall Survival
  • Figure 6.9: BOLERO-2 Safety
  • Figure 6.10: Intersection of mTOR and Estrogen Receptor Growth Pathways
  • Figure 6.11: Novartis Oncology Pipeline and pl3k Modulators in Development
  • Figure 6.12: Novartis Planned Filings 2012 and Later
  • Figure 6.13: Novartis Candidate PI3k Modulators
  • Figure 8.1: Halavans EMBRACE Trial: Improved Survival in Heavily Pretreated Patients
  • Figure 8.2: Halavens EMBRACE Trial: Improved Overall Survival
  • Figure 8.3: Halaven Effective Largely Irrespective of Prior Chemotherapy Experience
  • Figure 8.4: Halaven Safety
  • Figure 8.5: Access and Rationale for Adjuvant Chemotherapy in ER+ Breast Cancer
  • Figure 9.1: Personalized Drug Treatment
  • Figure 9.2: Approaches to Personalized Medicine
  • Figure 9.3: The Oncotype DX Assay Provides an Individualized Recurrence Score Result
  • Figure 9.4: Mammaprint Genes by Biological Function
  • Figure 9.5: Mammaprint Gene Signature Predicts Survival
  • Figure 9.6: ASCO-CAP Guidelines for Her2 Testing in Breast Cancer: Equivocal Results with IHC
  • Figure 9.7: ASCO-CAP Guidelines for Her2 Testing in Breast Cancer: Results by FISH
  • Figure 9.8: Personalized Medicine Drugs in Development
  • Figure 10.1: EGF and Her2 Receptors
  • Figure 10.2: Afatinib PFS Results in NSCCL
  • Figure 11.1: Healthcare Spending in the U.S. and Selected OECD Countries, 1970-2008
  • Figure 12.1: Growth of Breast Cancer Drug Sales in Major Markets, 2011-2018
  • Figure 12.2: Growth of Her2+ Drug Sales, 2011-2018
  • Figure 12.3: Declining Revenue for Branded Hormonal Therapies, 2011-2018
  • Figure 12.4: Declining Revenue for Aromatase Inhibitors, 2011-2018
  • Figure 12.5: The Her2-/Her2+ Drug Sales in the Major Seven Markets, 2011-2018
  • Figure 12.6: U.S. Shortages of Chemotherapy Drugs, 2005-2010
  • Figure 12.7: U.S. Market: Inpatient Breast Cancer Services, 2011-2021
  • Figure 12.8: U.S. Market: Outpatient Breast Cancer Services, 2011-2021
  • Figure 12.9: U.S. Market: Number of Chemotherapy Utilization, 2011-2021
  • Figure 12.10: Number of Chemotherapy Patients with Breast Cancer in the U.S., 2010-2020
  • Figure 12.11: Number of Breast Cancer Surgeries in the U.S., 2010-2020
  • Figure 12.12: U.S. Outpatient Breast Cancer Services Utilization Growth Rate, 2011-2021
  • Figure 12.13: Percent Growth for Standard Imaging Procedures in U.S. for Breast Cancer, 2011-2021
  • Figure 12.14: U.S. Market: Percent Growth fore Advanced Imaging in Breast Cancer, 2011-2021
  • Figure A2.1: Tumor Sizes
  • Figure A3.1: Breast Cancer in the U.S. by Race and Stage at Diagnosis
  • Figure A3.2: Female Breast Cancer Treatment Patterns by Stage
  • Figure A3.3: Five-Year Survival Rates for Breast Cancer Patients by Race and Stage at Diagnosis
  • Figure A3.4: Distribution of Colon and Rectum Cancer by Race and Stage at Diagnosis
  • Figure A3.5: Colon Cancer Treatment Patterns by Stage
  • Figure A3.6: Rectal Cancer Treatment Patterns by Stage
  • Figure A3.7: Five-Year Survival Rates for Colon and Rectal Cancer Patients by Race and Stage at Diagnosis
  • Figure A3.8: Distribution (%) of Non-Hodgkin Lymphoma Patients by Race and Stage at Diagnosis
  • Figure A3.9: Chemotherapy Use among Leukemia Patients by Age
  • Figure A3.10: Non-Hodgkin Lymphoma Treatment Patterns
  • Figure A3.11: Distribution (%) of Lung and Bronchus Cancer by Race and Stage at Diagnosis
  • Figure A3.12: Non-Small Cell Lung Cancer Treatment Patterns by Stage
  • Figure A3.13: Five-Year Survival Rates for Lung and Bronchus Cancer Patients
  • Figure A3.14: Distribution (%) of Melanoma by Race and Stage
  • Figure A3.15: Five-Year Survival Rates for Melanoma Patients by Race and Stage
  • Figure A3.16: Distribution of Prostate Cancer by Race and Stage
  • Figure A3.17: Prostate Cancer Primary Treatment Patterns by Age
  • Figure A3.18: Five-Year Survival Rates for Prostate Patients by Race and Stage
  • Figure A3.19: Distribution of Testicular Cancer by Race and Stage
  • Figure A3.20: Treatment Patterns for Testicular Cancer Patients
  • Figure A3.21: Treatment Patterns for Non-Seminomatous Testicular Cancer
  • Figure A3.22: Five-Year Survival Rates for Testicular Cancer Patients by Race and Stage
  • Figure A3.23: Distribution of Thyroid Cancer by Race and Stage
  • Figure A3.24: Five-Year Survival Rates for Thyroid Cancer Patients by Race and Stage
  • Figure A3.25: Distribution of Urinary Bladder Cancer by Race and Stage
  • Figure A3.26: Muscle Invasive Bladder Cancer Treatment Patterns
  • Figure A3.27: Five-Year Survival Rates for Urinary Bladder Cancer Patients by Race and Stage
  • Figure A3.28: Distribution of Uterine Corpus Cancer by Race and Stage
  • Figure A3.29: Uterine Cancer Treatment Patterns by Stage
  • Figure A3.30: Five-Year Survival Rates for Uterine Corpus Cancer Patients by Race and Stage
  • Figure A3.31: Domains of Quality of Life
  • Figure A3.32: Observed-to-Expected Ratios for Subsequent Cancers by Site, Sex and Age 20 and Older
  • Figure A3.33: Observed-to-Expected Ratios for Subsequent Cancers by Primary Site
  • Figure A3.34: Unmet Caregiver Needs by Time Since Diagnosis
  • Figure A4.1: Estimates of National Expenditures for Cancer Care in 2010 by Site
  • Figure A4.2: National Expenditure for Cancer Care in 2010 by Site and Phase of Care
  • Figure A4.3: Proportion of National Expenditure for Cancer Care in 2010 by Site and Phase of Care
  • Figure A4.4: Percentage of Medicare Payments in the First Year Following Diagnosis for Cancer Care by Type of Service in 2002
  • Figure A5.1: Oncology Drugs and CDX Launches, 1995-2011
  • Figure A5.2: Major Oncology Firms R&D Budgets, 2012
  • Figure A5.3: Oncology Pipeline-Drug Development Strategy
  • Figure A5.4: Oncology Drugs in Development and Future Launches
  • Figure A5.5: Launches, Launch Position and Drugs with CDX, 2012-2017
  • Figure A5.6: Past Oncology Launches vs. Forecast, 1997-2016

INDEX OF TABLES

  • Table 2.1: Factors That Increase the Risk of Breast Cancer in Women
  • Table 2.2: Age-Specific Probabilities of Developing Invasive Breast Cancer
  • Table 3.1: Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites, 2008
  • Table 3.2: Number of New Cancer Cases and Deaths by Geography, 2008
  • Table 3.3: Estimated New Female Breast Cancer Cases and Death by Age in the U.S., 2011
  • Table 3.4: Female Breast Cancer Incidence and Mortality Rates by Race, Ethnicity and State
  • Table 3.5: Five-Year Cause Specific Survival Rate by Race/Ethnicity
  • Table 3.6: Mammography Screening Prevalence by Age and Poverty Status in the U.S., 1987-2010
  • Table 3.7: Breast Cancer Incidence Rates per 100,000 Populations in U.K., 2009
  • Table 3.8: Number of Breast Cancer Patients in U.K., 2009-2010
  • Table 3.9: Metastatic Breast Cancer Patients Who Receive Later Lines of Chemotherapy in China
  • Table 3.10: Top-Three Chemotherapy Regimens for Breast Cancer in China
  • Table 3.11: Top-Three Stage IV Hormone Therapies in China
  • Table 3.12: Breast Cancer Drugs Available in China
  • Table 3.13: Utilization of Traditional Chinese Medicine for Breast Cancer
  • Table 3.14: Incident Breast Cancer Cases in Seven Major Markets, 2010-2019
  • Table 4.1: Selected, Partial List of Chemotherapies
  • Table 4.2: Currently Available Drugs for the Treatment of Breast Cancer
  • Table 5.1: Key Points About Herceptin
  • Table 5.2: Incidence of Congestive Heart Failure in Adjuvant Breast Cancer Studies
  • Table 5.3: Incidence of Cardiac Disfunction in Metastatic Breast Cancer Studies
  • Table 5.4: Selected Ongoing Pertuzumab Studies
  • Table 5.5: Key Points about Pertuzumab (Omnitarg)
  • Table 5.6: Key Efficacy Results from Tykerbs EGF100151 Study
  • Table 5.7: Tykerb: Recommendations for Diarrhea Management
  • Table 5.8: Tykerb (Lapatinib): Key Points
  • Table 7.1: Drugs Targeting Angiogenesis
  • Table 8.1: Selected Chemotherapies in Breast Cancer
  • Table 8.2: Currently Available Chemotherapies
  • Table 8.3: Chemotherapies Reformulations
  • Table 9.1: Timeline for Development of Companion Diagnostics
  • Table 9.2: Personalized Medicine at Nexus Point
  • Table 9.3: Percentage of Non-Responders in Various Drug Classes
  • Table 9.4: High-Profile Drug Withdrawals from the Marketplace
  • Table 9.5: Selected List of Personalized Medicine Tests
  • Table 9.6: ASCO-CAP Guidelines for Her2 Testing in Breast Cancer: Interpretation of Results
  • Table 9.7: Potential Benefits of Biomarkers as Companion Diagnostics
  • Table 9.8: Utility of Biomarker as Companion Diagnostics to Drug Development
  • Table 10.1: Selected Drugs and Classes in Development, Agents in Phase II or Later
  • Table 10.2: PI3k/mTOR Targeted Drugs in Development
  • Table 10.3: Breast Cancer Vaccines in Development
  • Table 10.4: Emerging Drugs and Selected Side Effect Profiles
  • Table A2.1: Staging of Breast Cancer
  • Table A3.1: Estimated Number of Cancer Survivors in the U.S. as of January 1, 2012
  • Table A3.2: Estimated Numbers of U.S. Cancer Survivors by Site as of January 1, 2012
  • Table A3.3: Estimated U.S. Cancer Survivors by Sex and Time since Diagnosis as of January 1, 2012
  • Table A3.4: Estimated U.S. Cancer Survivors by Sex and Age as of January 1, 2012
  • Table A5.1: Annual Revenue of Top Oncology Franchises, 2011
Back to Top